| Robert J Lenox, MD | |
|
90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 | |
| (315) 464-3835 | |
| (315) 464-3837 |
| Full Name | Robert J Lenox |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 90 Presidential Plz, Syracuse, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710917133 | NPI | - | NPPES |
| 00643994 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 155670 (New York) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 155670 (New York) | Primary |
| Entity Name | Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063468239 PECOS PAC ID: 3274445796 Enrollment ID: O20031104000051 |
News Archive
In 2009, it was estimated that a total of 22,070 new cases of brain and other CNS tumors were diagnosed. Pituitary adenomas represent one of the most common brain tumors. Large studies report that approximately 10-20 percent of the population harbors a pituitary tumor. According to the Central Brain Tumor Registry of the United States, 13.4 percent of all brain and CNS tumors diagnosed in 2009 were located in the pituitary.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.
Fitch Ratings has downgraded to 'BBB+' the underlying rating on approximately $464 million outstanding bonds issued by the Louisiana Public Facilities Authority on behalf of Ochsner Clinic Foundation (OCF) ($380 million series 2007A) and Ochsner Community Hospitals (OCH) ($83.9 million series 2007B).
COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert J Lenox, MD 90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 Ph: (315) 464-3835 | Robert J Lenox, MD 90 Presidential Plz, Firm C, Syracuse, NY 13202-2240 Ph: (315) 464-3835 |
News Archive
In 2009, it was estimated that a total of 22,070 new cases of brain and other CNS tumors were diagnosed. Pituitary adenomas represent one of the most common brain tumors. Large studies report that approximately 10-20 percent of the population harbors a pituitary tumor. According to the Central Brain Tumor Registry of the United States, 13.4 percent of all brain and CNS tumors diagnosed in 2009 were located in the pituitary.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.
Fitch Ratings has downgraded to 'BBB+' the underlying rating on approximately $464 million outstanding bonds issued by the Louisiana Public Facilities Authority on behalf of Ochsner Clinic Foundation (OCF) ($380 million series 2007A) and Ochsner Community Hospitals (OCH) ($83.9 million series 2007B).
COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.
› Verified 6 days ago
Courtney Myers, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |